The Role of Biomarkers in NF1-PN Care

EP: 1.Genetic And Molecular Mechanisms of NF1

EP: 2.Diagnosis, Epidemiology, And Risk Factors Of NF1-PN

EP: 3.Hallmark Symptoms and Clinical Features of NF1-PN

EP: 4.Quality of Life in Patients With NF1-PN

EP: 5.Key Clinical Considerations in NF1-PN Management

EP: 6.Unmet Needs of Patients Living With NF1-PN

EP: 7.Main Goals in the Management of NF1-PN

EP: 8.Rationale for MEK Inhibitors and Surgery

EP: 9.Selumetinib as a Therapeutic Option for NF1-PN

EP: 10.Examining Combination Therapy In NF1-PN

EP: 11.Barriers to Optimal NF1-PN Care for Patients

EP: 12.Lessons From Previously Used Therapies In NF1-PN

EP: 13.Novel FDA-Approved Therapy for NF1-PN

EP: 14.Mirdametinib as a Therapy for Patients With NF1-PN

Now Viewing

EP: 15.The Role of Biomarkers in NF1-PN Care

Summary for Physicians

Patient Selection and Biomarkers
Biomarkers can help identify patients most likely to benefit from therapies like mirdametinib or gene therapies by targeting those with RAS/MEK/ERK activation or specific NF1 mutations. Genetic testing can assess NF1 mutations and identify patients with progressive, symptomatic neurofibromatosis type 1–associated plexiform neurofibromas (NF1-PN) who are likely to respond to targeted therapies. Additionally, tumor profiling (eg, assessing the RAS mutation status) may help refine treatment choices, allowing for more personalized and effective management of neurofibromatosis type 1–associated plexiform neurofibromas (NF1-PN).